Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.

M-ERA.NET 3 aims at coordinating the research efforts in the participating EU Member States, Regions, and Associated States in materials research and innovation, including materials for future batteries, to support the circular economy and Sustainable Development Goals. A large network of national and regional funding organisations from 25 EU Members States, 4 Associated States and 6 countries outside Europe will implement a series of annual joint calls to fund excellent innovative transnational RTD cooperation, including one call for proposals with EU co-funding and additional non-cofunded calls. Continuing the activities started under the predecessor project M-ERA.NET 2 (3/2016-2/2021), the M-ERA.NET 3 consortium will address emerging technologies and related applications areas, such as - for example- surfaces, coatings, composites, additive manufacturing or integrated materials modelling. Research on materials supporting the large scale research initiative on future battery technologies will be particularly highlighted as a main target of the cofunded call (Call 2021) with a view to supporting in particular SDG 7 (“Affordable and clean energy”) by enabling electro mobility through sustainable energy storage technology and SDG 9 (“Industrial innovation and infrastructure”) by enhancing scientific research and upgrading the technological capabilities of industrial sectors. Several relevant action plans and initiatives will serve as programmatic guides for M-ERA.NET 3 when defining the joint activities, such as the Circular Economy Action Plan, the 2030 Agenda for Sustainable Development and its 17 Sustainable Development Goals, the EC communication “A clean planet for all”, and the “European Green Deal”. The total mobilised public call budget is expected to reach 150 million € with additional private investment of 50 million €. Thus, the leverage effect of the EU contribution will reach a factor of 13, exceeding by far the minimum required factor of 5.

The ERA-NET Cofund BlueBio will act to unlock the potential of aquatic bio-resources to create jobs, economic growth and provide food, nutrition and bio-based products and services. Thus, paving the way for a sustainable and competitive Blue Bioeconomy in Europe. The goal is to identify new and improve existing ways of bringing bio-based products and services to the market and find new ways of creating value in the Blue bioeconomy. The objectives of BlueBio are to establish a coordinated R&D funding scheme that will strengthen Europe’s position in this complex economic field in a global market. This will primarily be achieved by engaging funding agencies to implement a co-funded call focusing on Blue Knowledge and technological developments to respond to needs and gaps for R&I. The consortium has committed budgets making a strong co-funded call leveraging well the Commission's requests. BlueBio builds upon the networks, achievements and strategies obtained in the COFASP and ERA-MBT ERA-NETs and JPI Oceans, and will leverage the JPI Oceans role as a coordination platform. The consortium aims to implement 2-4 additional calls, developed through stakeholder engagement, and identifying new funding initiatives. BlueBio will implement a range of related activities which can add value to the cofounded projects and better address the impact of R&I projects. BlueBio will enhance valorisation from the actors in the Blue Bioeconomy sector, identify and address R&I needs of industry and society. Communications activities will support BlueBio and the funded projects to realise tangible impacts. Emphasis will be placed on the creation of pre-commercial outputs aimed at accelerating commercialisation and competitive deployment. BlueBio's directions and legacy will be informed by strategic forward-looking processes involving all stakeholders in identifying needs and gaps along the value chains.